Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
W6QK ACC-APG
Contract Value
Not provided
Codes & Classification
Solicitation Number
W911SR-26-R-HEAL
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AC13
Additional Details
Documents2
The Department of the Army, through the Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), has issued a Special Notice inviting participation in the Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. This ongoing, open announcement—procurement identifier W911SR-26-R-HEAL—seeks to establish a robust network of pre-qualified partners to accelerate the development, testing, and deployment of advanced CBRN medical defense solutions. The initiative is administered by W6QK ACC-APG, a federal contracting office under the Department of Defense.
**Purpose and Scope**
The primary objective of this PBA is to foster a collaborative framework that supports the rapid advancement and fielding of next-generation medical countermeasures (MCMs) and diagnostics to protect military personnel against a broad spectrum of CBRN threats. The agreement is designed to be agile, accommodating a wide range of acquisition strategies and technologies—from early-stage prototyping through late-stage development and FDA licensure or clearance. The scope encompasses both therapeutic and diagnostic solutions, with an emphasis on integrated, layered defense capabilities that enhance warfighter resilience in complex and evolving threat environments.
**Key Requirements and Objectives**
The CBRN MCM PBA seeks innovative solutions across several domains:
- **Host-Targeted Resilience:** Development of threat-agnostic MCMs that enhance physiological protection and treatment by targeting critical host systems. Priority is given to drug candidates suitable for rapid deployment in austere environments, with simplified administration routes (oral, intranasal, autoinjector) and mechanisms addressing neurological, respiratory, immune, hematologic, vascular, and cellular stress pathways.
- **Threat-Targeted Neutralization:** Creation of broad-spectrum countermeasures capable of neutralizing CBRN agents through pre- or post-exposure prophylaxis or acute treatment. Desired attributes include environmental stability (eliminating cold-chain requirements), immediate usability in operational settings, and simplified dosing regimens for rapid threat mitigation.
- **Diagnostic Development:** Advancement of agile, point-of-need diagnostic platforms and decision support tools. Solutions should be portable, user-friendly, and operable in austere environments by minimally trained personnel. Areas of interest include pathogen-specific and host-response assays, antimicrobial resistance testing, severity-of-illness diagnostics, and early detection modalities to enable timely medical intervention.
**Expected Deliverables**
Participants are expected to contribute to the development and maturation of medical devices, drugs, biologics, and diagnostic systems that meet the outlined requirements. Deliverables may include:
- Comprehensive product descriptions, efficacy data, regulatory and clinical status, manufacturing capabilities, and company profiles for MCM developers.
- Summaries of core capabilities, regulatory experience, and infrastructure for development support collaborators (CROs/CDMOs).
- Detailed specifications, performance data, ruggedization assessments, regulatory pathways, and cybersecurity compliance for diagnostic collaborators.
**Eligibility and Collaboration**
The announcement is open to a broad spectrum of entities, including:
- MCM developers at all stages of product development (from Phase I through FDA licensure).
- Contract research and manufacturing organizations with expertise in preclinical and clinical development, regulatory submissions, and advanced modeling.
- Academic, industry, and non-profit developers of diagnostic platforms and enabling technologies.
- Organizations specializing in clinical sample management, device validation, biosafety testing, regulatory clearances, and tactical network integration.
- Technology partners willing to share intellectual property with the U.S. Government to accelerate assay development and diagnostic expansion.
**Submission Process**
Interested parties must submit a white paper (maximum five pages, excluding cover page) addressing the relevant areas for their category of participation and indicating willingness to collaborate within the PBA. Submissions should be sent to [email protected]. Technical and administrative inquiries may be directed to Hunter Robinson ([email protected]) or Alexander Mayatte ([email protected]).
**Contracting and Administrative Details**
- **NAICS Code:** 541714 – Research and Development in Biotechnology (except Nanobiotechnology)
- **Product Service Code:** AC13
- **Contracting Entity:** W6QK ACC-APG, Department of the Army
- **Authority:** Awards may be made under 10 U.S.C. §§ 4021, 4022, and 4023, and are not subject to the Competition in Contracting Act of 1984.
- **SAM Registration:** Required for all prospective awardees prior to invoicing and through final payment.
**Special Considerations**
This is a continuous, open announcement with no submission deadline unless otherwise specified. Previous submissions under the former Threat Agnostic Host-Directed Therapeutics/HEALER PBA remain valid. Acceptance into the PBA enables eligibility for project orders under any supported program, facilitating long-term collaboration with the Government.
**Summary**
This opportunity represents a strategic initiative by the Department of Defense to build a resilient, integrated defense against CBRN threats through sustained collaboration with industry, academia, and non-profit partners. Contractors with capabilities in advanced medical countermeasure development, diagnostics, and supporting services are encouraged to evaluate their alignment with the program’s vision and submit proposals to join this critical national security effort.
For further details and to access the official notice, visit: [SAM.gov Opportunity ID a8706a7e4b1d4b08bb5a9daf9004f688](https://sam.gov/opp/a8706a7e4b1d4b08bb5a9daf9004f688).